Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis
ARSis sequential therapy did not significantly differ from ARSis combined therapy in improving OS and PFS among patients with mHSPC, and thus can be considered as a viable treatment option.
Authors
- Guan Chun Wang
- Yu Qiao Wang
- Zhaogang Yang (ORCID: https://orcid.org/0000-0002-6350-4455)
- Lei Wang (ORCID: https://orcid.org/0000-0003-2402-2338)
- Xian Zhang (ORCID: https://orcid.org/0000-0002-2743-1738)
- Chunsheng Li (ORCID: https://orcid.org/0000-0002-9425-775X)
- Hua Liu (ORCID: https://orcid.org/0000-0002-7936-5330)
- Chun Xing Li
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- China Rehabilitation Research Center (CN)
- PLA 306 Hospital (CN)
- Aerospace Center Hospital (CN)
- Peking University Shougang Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fphar.2024.1462360
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00